Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Summit Therapeutics stock is off to a slow start in 2025, but it still trades at a massive $13 billion valuation. The biotech ...

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...

Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

A very bullish analyst move was the news generally responsible for Summit Therapeutics' (NASDAQ: SMMT) healthy mid-week stock price pop. The person behind the news was Evercore ISI pundit Cory Kasimov ...

Although new U.S. tariffs on Canada, Mexico, and China are putting pressure on markets, investors are shifting toward ...

The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.

Doctor, doctor, give me the news, Hims & Hers Health (HIMS) has got bad case of the stock market blues ... up competition involving weight-loss drugs. The Food and Drug Administration two years ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going to take a look at where Perrigo Company plc (NYSE:PRGO) stands against ...

DexCom received a warning letter from the Food and Drug Administration following inspections of two of its plants.